Shares in Glenmark Pharmaceuticals were trading marginally higher after the company said that it has been granted tentative approval by the US health regulator to sell Rufinamide, which is used to treat seizures caused by Lennox-Gastaut syndrome.
"Glenmark...has been granted tentative approval last week by the United States Food and Drug Administration (USFDA) for its Rufinamide tablets," the company said in a BSE filing.
The approval has been granted for the tablets in 200 mg and 400 mg strengths. Rufinamide is a therapeutic equivalent of Banzel tablets of Eisai.
Glenmark further said: "Under the terms of a settlement agreement between Glenmark and Eisai, Glenmark will be permitted to market this product in the US on May 30, 2022 or potentially earlier under certain circumstances."